camptothecin has been researched along with Ascites in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Imai, H; Ishioka, C; Kasahara, Y; Kawamura, Y; Komine, K; Ouchi, K; Saijo, K; Sasaki, K; Shirota, H; Takahashi, M; Takenaga, N; Taniguchi, SH; Yoshida, Y | 1 |
| Beinse, G; Bonnetain, F; Borg, C; Bouché, O; Cleau, D; d'Engremont, C; de Mestier, L; Dupont-Gossart, AC; Fein, F; Heyd, B; Lakkis, Z; Louvet, C; Meurisse, A; Neuzillet, C; Rousseau, B; Tournigand, C; Vernerey, D; Vienot, A | 1 |
| Chen, J; Chen, S; Xi, W; Xu, W; Yin, G | 1 |
| Boku, N; Fukutomi, A; Hironaka, S; Kojima, T; Machida, N; Onozawa, Y; Sakamoto, T; Shimoyama, R; Taku, K; Todaka, A; Tomita, H; Tsushima, T; Yamazaki, K; Yasui, H | 1 |
| Asukai, K; Hasegawa, I; Horiguchi, N; Koguchi, H; Matsunaga, S; Miura, A; Ohno, T; Sakakibara, K; Shimizu, S; Togawa, S | 1 |
| Kaneda, N; Konishi, H; Kurita, A; Matsuzaki, T; Takagi, A | 1 |
| Ebuchi, M; Hasegawa, K; Maruyama, M; Nagahama, T; Natsui, S; Ochiai, T; Takashima, I | 1 |
| Kuga, H; Kumazawa, E; Ochi, Y; Shiose, Y | 1 |
| Geng, M; Ji, YB; Jiang, JS; Li, H; Lou, GY; Ma, T; Xi, WQ; Xia, HQ; YeE, ZB | 1 |
| Baba, H; Ebuchi, M; Kure, N; Maruyama, M; Nagahama, T; Toukairin, Y; Yoshida, T | 1 |
1 trial(s) available for camptothecin and Ascites
| Article | Year |
|---|---|
Clinical therapeutic effect and biological monitoring of p53 gene in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Ascites; Camptothecin; Carcinoma, Hepatocellular; Catheters, Indwelling; Chemoembolization, Therapeutic; Female; Genes, p53; Genetic Therapy; Humans; Iliac Artery; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2014 |
9 other study(ies) available for camptothecin and Ascites
| Article | Year |
|---|---|
FOLFIRI Chemotherapy for Patients With Metastatic Urachal Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Outcome | 2023 |
Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Camptothecin; Cancer Pain; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Health Status; Humans; Irinotecan; Jaundice; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Nomograms; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Prospective Studies; Retreatment; Risk Factors; Smoking; Survival Rate | 2017 |
Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Camptothecin; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Paclitaxel; Recurrence; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Rate; Treatment Outcome; Young Adult | 2009 |
[A case of gastric cancer with peritoneal dissemination who achieved long survival from control of ascites for over 2 years by successive treatments with S-1 in combination with docetaxel as first-line followed by irinotecan in combination with cisplatin
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Camptothecin; Cisplatin; Docetaxel; Drug Combinations; Fatal Outcome; Humans; Irinotecan; Male; Oxonic Acid; Peritoneal Neoplasms; Salvage Therapy; Stomach Neoplasms; Taxoids; Tegafur | 2012 |
PEGylated liposome IHL-305 markedly improved the survival of ovarian cancer peritoneal metastasis in mouse.
Topics: Animals; Antineoplastic Agents; Ascites; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; ErbB Receptors; Female; Humans; Irinotecan; Liposomes; Mice; Ovarian Neoplasms; Peritoneal Neoplasms; Polyethylene Glycols; Xenograft Model Antitumor Assays | 2012 |
[Pharmacokinetic study of CPT-11, SN-38 and SN-38 glucuronide in the ascites, plasma and bile after intraperitoneal administration of CPT-11].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Ascites; Bile; Camptothecin; Glucuronides; Humans; Infusions, Parenteral; Irinotecan; Male; Stomach Neoplasms | 2002 |
A possible mechanism for the long-lasting antitumor effect of the macromolecular conjugate DE-310: mediation by cellular uptake and drug release of its active camptothecin analog DX-8951.
Topics: Animals; Antineoplastic Agents; Ascites; Camptothecin; Chromatography, High Pressure Liquid; Endocytosis; Fibrosarcoma; Fluorescence; Injections, Intraperitoneal; Lysosomes; Macrophages; Mice; Microscopy, Confocal; Neoplasm Transplantation; Tumor Cells, Cultured | 2005 |
[In vitro chemo-sensitivity MTT assay guided intraperitoneal chemotherapy for malignant ascites].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Ascites; Camptothecin; Cell Survival; Colorectal Neoplasms; Docetaxel; Female; Humans; Injections, Intraperitoneal; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Stomach Neoplasms; Taxoids; Tumor Cells, Cultured | 2006 |
[Experimental study on CPT-11 intraperitoneal chemotherapy--metabolism of CPT-11 in malignant ascites].
Topics: Antineoplastic Agents, Phytogenic; Ascites; Camptothecin; Humans; Infusions, Parenteral; Irinotecan; Peritoneal Neoplasms; Stomach Neoplasms | 2000 |